This case was reported by a consumer via call center representative and described the occurrence of neuropathy peripheral in a 71-year-old female patient who received SHINGRIX for prophylaxis.  On 29th August 2018, the patient received the 1st dose of SHINGRIX. On 29th August 2018, less than a day after receiving SHINGRIX, the patient experienced neuropathy peripheral (serious criteria GSK medically significant), dizziness, feeling unwell, appetite absent, headache, shivering, poor sleep, balance disorder, influenza and cold. On 30th August 2018, the patient experienced unable to walk and lack of coordination. On 1st September 2018, the patient experienced feeling hot and cold and movements abnormal. On an unknown date, the patient experienced nausea, blurred vision, memory impairment, tremor and feeling hungry. On an unknown date, the outcome of the neuropathy peripheral, dizziness, unable to walk, lack of coordination, feeling unwell, appetite absent, nausea, headache, shivering, poor sleep, blurred vision, memory impairment, tremor, feeling hot and cold, movements abnormal, feeling hungry, balance disorder and influenza were unknown and the outcome of the cold was recovering/resolving. It was unknown if the reporter considered the neuropathy peripheral, dizziness, unable to walk, lack of coordination, feeling unwell, appetite absent, nausea, headache, shivering, poor sleep, blurred vision, memory impairment, tremor, feeling hot and cold, movements abnormal, feeling hungry, balance disorder, influenza and cold to be related to SHINGRIX. Additional details were provided as follows: This case was reported by the patient for herself. The patient received SHINGRIX vaccine on Wednesday, in the left arm. She described that she could feel the medication go into her arm. She was able to drive home and park her car. However, when she attempted to walk to her apartment, she had to sit on a bench outside because she did not feel well. She described that she felt "swimmy", felt dizzy and felt off balance. She was finally able to walk into her apartment but said she "did not feel that like she was all there".  She could not eat and she felt sick. She tried to eat and drink water.  Through the night and the next morning she had headaches, she was cold, shivering, and did not sleep well. When the patient got up the next morning after vaccination, she described that "she did not have two feet on the floor". She could not walk without holding on to things. Her coordination was off. By Saturday, 3 days after receiving SHINGRIX, she was writhing on her bed, she had neuropathy in her feet, and she kept getting hot and cold. She went to the physician last Wednesday before reporting date and was doing all she could do at this point for the symptoms. Less than a month after receiving SHINGRIX, she said that at times her eyes were blurry and the vaccination had affected her memory. She felt nauseous and hungry at the same time, shaking, felt dizzy. She felt like she had the worst case of the flu. She did feel she was getting a little better at the reporting time. The reporter gave permission for her physician to be contacted along with contact details but additional details were not obtained. The reporter was difficult to follow as she was upset regarding her experience and wanted to know why GlaxoSmithKline released this product on the market without testing it on a larger population of people.